1
|
Tompson DJ, Davies C, Scott NE, Cannons EP, Kostapanos M, Gross AS, Powell M, Ino H, Shimamura R, Ogura H, Nagakubo T, Igarashi H, Nakano A. Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects. Eur J Drug Metab Pharmacokinet 2020; 46:71-83. [PMID: 33165774 PMCID: PMC7811991 DOI: 10.1007/s13318-020-00652-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Background and Objectives GSK2982772 is an oral small-molecule RIPK1 inhibitor with potential therapeutic efficacy in immune-mediated inflammatory diseases (IMIDs). An inter-ethnic comparison of GSK2982772 pharmacokinetics was conducted based on data from Western (Study 1) and Japanese subjects (Study 2). Methods Both studies were single-centre, randomised, double-blind, placebo-controlled studies with objectives to assess the safety and characterise the pharmacokinetics of GSK2982772. Western subjects in Study 1 (NCT03305419), Part A (N = 15), were randomly assigned to receive 120 mg three times daily (TID), 240 mg TID, or 360 mg twice daily (BID) doses of GSK2982772, or placebo (TID or BID) for 1 day. Part B subjects (N = 47) received GSK2982772 120 mg TID, 240 mg TID, or placebo TID for 14 days. Japanese subjects in Study 2 (N = 13) (NCT03590613) were randomly assigned to receive TID doses of GSK2982772 60, 120, 240 mg TID or placebo TID for 1 day. Results GSK2982772 was well tolerated and adverse events were generally mild. Maximum observed plasma drug concentration (Cmax), time to reach Cmax (Tmax), area under the plasma drug concentration versus time curve after the first GSK2982772 dose (AUC(0–7)) of 120 and 240 mg, and (AUC(0–24)) values for the 120 and 240 mg TID doses over a single day were similar in Japanese and Western subjects. Conclusions The pharmacokinetics and tolerability of GSK2982772 were similar between Western and Japanese subjects, justifying inclusion of Japanese subjects in future global clinical studies to assess the therapeutic potential of RIPK1 inhibition for the treatment of IMIDs. Clinical Trials: NCT03305419 and NCT03590613 available from http://www.clinicaltrials.gov. Electronic supplementary material The online version of this article (10.1007/s13318-020-00652-2) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Debra J Tompson
- Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, UK.
| | - Carwyn Davies
- Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Sydney, NSW, Australia
| | - Nicola E Scott
- Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, UK
| | - Edward P Cannons
- Global Clinical Sciences and Delivery, GlaxoSmithKline, Medicines Research Centre, Stevenage, Hertfordshire, UK
| | - Michalis Kostapanos
- Clinical Care Unit Cambridge, GlaxoSmithKline, and Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, UK
| | - Annette S Gross
- Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Sydney, NSW, Australia
| | - Marcy Powell
- Safety and Medical Governance, GlaxoSmithKline, Research Triangle Park, NC, USA
| | - Hiroko Ino
- Clinical Pharmacology, Medicines Development, GlaxoSmithKline, Tokyo, Japan
| | - Ryutaro Shimamura
- Clinical Pharmacology, Medicines Development, GlaxoSmithKline, Tokyo, Japan
| | - Hirofumi Ogura
- Clinical Pharmacology, Medicines Development, GlaxoSmithKline, Tokyo, Japan
| | - Takashi Nagakubo
- Biomedical Data Sciences Department, GlaxoSmithKline, Tokyo, Japan
| | - Harue Igarashi
- Pre-Clinical Development Department, GlaxoSmithKline, Tokyo, Japan
| | | |
Collapse
|
2
|
Weisel K, Scott NE, Tompson DJ, Votta BJ, Madhavan S, Povey K, Wolstenholme A, Simeoni M, Rudo T, Richards-Peterson L, Sahota T, Wang JG, Lich J, Finger J, Verticelli A, Reilly M, Gough PJ, Harris PA, Bertin J, Wang ML. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers. Pharmacol Res Perspect 2018; 5. [PMID: 29226626 PMCID: PMC5723699 DOI: 10.1002/prp2.365] [Citation(s) in RCA: 87] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 09/25/2017] [Indexed: 12/22/2022] Open
Abstract
GSK2982772 is a highly selective inhibitor of receptor‐interacting protein kinase 1 (RIPK1) being developed to treat chronic inflammatory diseases. This first‐in‐human study evaluated safety, tolerability, pharmacokinetics (PK), and exploratory pharmacodynamics (PD) of GSK2982772 administered orally to healthy male volunteers. This was a Phase I, randomized, placebo‐controlled, double‐blind study. In Part A, subjects received single ascending doses of GSK2982772 (0.1‐120 mg) or placebo in a crossover design during each of 4 treatment periods. In Part B, subjects received repeat doses of GSK2982772 (20 mg once daily [QD] to up to 120 mg twice daily [BID]) or placebo for 14 days. Part C was an open‐label relative bioavailability study comparing 20‐mg tablets vs capsules. Safety, tolerability, pharmacokinetics (PK), RIPK1 target engagement (TE), and pharmacodynamics (PD) were assessed. The most common adverse events (AEs) were contact dermatitis and headache. Most AEs were mild in intensity, and there were no deaths or serious AEs. The PK of GSK2982772 was approximately linear over the dose range studied (up to 120 mg BID). There was no evidence of drug accumulation upon repeat dosing. Greater than 90% RIPK1 TE was achieved over a 24‐hour period for the 60‐mg and 120‐mg BID dosing regimens. Single and repeat doses of GSK2982772 were safe and well tolerated. PK profiles showed dose linearity. The high levels of RIPK1 TE support progression into Phase II clinical trials for further clinical development.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Todd Rudo
- GlaxoSmithKline, Collegeville, PA, USA
| | | | | | | | - John Lich
- GlaxoSmithKline, Collegeville, PA, USA
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Cramer SC, Abila B, Scott NE, Simeoni M, Enney LA. Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Stroke. Stroke 2013; 44:1337-42. [DOI: 10.1161/strokeaha.111.674366] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose—
Restorative therapies have the potential to improve function and reduce disability after stroke with a wide therapeutic window. The current study evaluated GSK249320, a monoclonal antibody that blocks the axon outgrowth inhibition molecule myelin-associated glycoprotein and also protects oligodendrocytes.
Methods—
Patients with mild-moderate stroke were randomized to intravenous GSK249320 (1, 5, or 15 mg/kg per infusion, in escalating cohorts of 8–9 subjects) versus placebo (n=17). Infusion 1 was 24 to 72 hours after stroke; infusion 2 was 9±1 days later. The primary objective evaluated safety and tolerability, and the secondary objectives evaluated immunogenicity, pharmacokinetics, biomarkers, neurophysiology, and motor function.
Results—
Baseline (n=42) characteristics were similar across treatment groups. No safety concerns were found based on adverse events, examination, vital signs, ECG, nerve conduction tests, brain imaging, motor function testing, and laboratory studies. Two of the 25 subjects dosed with GSK249320 developed transient antidrug antibodies after infusion 1. The pharmacokinetics profile was as expected for an IgG1 type monoclonal antibody. Serum levels of the biomarker S100β did not differ between groups. Global outcome measures were similar across groups. Modality-specific end points could be consistently measured in the first few days after stroke, and one of these, gait velocity, demonstrated a trend toward improvement with GSK249320 compared with placebo.
Conclusions—
GSK249320 was generally well tolerated. No major safety issues were identified in this first study of a monoclonal antibody to modulate the neurobiology of brain repair after stroke. Future studies might explore the efficacy of GSK249320 as a restorative therapy for stroke.
Clinical Trial Registration—
URL:
http://www.clinicaltrials.gov
. Unique Identifier: NCT00833989.
Collapse
Affiliation(s)
- Steven C. Cramer
- From the Departments of Neurology and Anatomy & Neurobiology, University of California, Irvine, CA (S.C.C.); GlaxoSmithKline, Biopharm Translational Medicine, Stevenage, United Kingdom (B.A.); GlaxoSmithKline, Biopharm Clinical Statistics, Stevenage, United Kingdom (N.E.S.); GlaxoSmithKline, Clinical Pharmacology Modeling and Simulation, Stockley Park, United Kingdom (M.S.); and GlaxoSmithKline, Neurosciences MDC, Research Triangle Park, NC (L.A.E.)
| | - Bams Abila
- From the Departments of Neurology and Anatomy & Neurobiology, University of California, Irvine, CA (S.C.C.); GlaxoSmithKline, Biopharm Translational Medicine, Stevenage, United Kingdom (B.A.); GlaxoSmithKline, Biopharm Clinical Statistics, Stevenage, United Kingdom (N.E.S.); GlaxoSmithKline, Clinical Pharmacology Modeling and Simulation, Stockley Park, United Kingdom (M.S.); and GlaxoSmithKline, Neurosciences MDC, Research Triangle Park, NC (L.A.E.)
| | - Nicola E. Scott
- From the Departments of Neurology and Anatomy & Neurobiology, University of California, Irvine, CA (S.C.C.); GlaxoSmithKline, Biopharm Translational Medicine, Stevenage, United Kingdom (B.A.); GlaxoSmithKline, Biopharm Clinical Statistics, Stevenage, United Kingdom (N.E.S.); GlaxoSmithKline, Clinical Pharmacology Modeling and Simulation, Stockley Park, United Kingdom (M.S.); and GlaxoSmithKline, Neurosciences MDC, Research Triangle Park, NC (L.A.E.)
| | - Monica Simeoni
- From the Departments of Neurology and Anatomy & Neurobiology, University of California, Irvine, CA (S.C.C.); GlaxoSmithKline, Biopharm Translational Medicine, Stevenage, United Kingdom (B.A.); GlaxoSmithKline, Biopharm Clinical Statistics, Stevenage, United Kingdom (N.E.S.); GlaxoSmithKline, Clinical Pharmacology Modeling and Simulation, Stockley Park, United Kingdom (M.S.); and GlaxoSmithKline, Neurosciences MDC, Research Triangle Park, NC (L.A.E.)
| | - Lori A. Enney
- From the Departments of Neurology and Anatomy & Neurobiology, University of California, Irvine, CA (S.C.C.); GlaxoSmithKline, Biopharm Translational Medicine, Stevenage, United Kingdom (B.A.); GlaxoSmithKline, Biopharm Clinical Statistics, Stevenage, United Kingdom (N.E.S.); GlaxoSmithKline, Clinical Pharmacology Modeling and Simulation, Stockley Park, United Kingdom (M.S.); and GlaxoSmithKline, Neurosciences MDC, Research Triangle Park, NC (L.A.E.)
| |
Collapse
|
4
|
Scott NE, Haskins SC, Aldrich J. ANALYZER-CALCULATED OXYHEMOGLOBIN SATURATION AND OXYGEN CONTENT VALUES ARE COMPARABLE TO HAND-CALCULATED VALUES USING A NORMAL CANINE OXYHEMOGLOBIN DISSOCIATION RELATIONSHIP IN UNSEDATED HEALTHY DOGS. J Vet Emerg Crit Care (San Antonio) 2004. [DOI: 10.1111/j.1476-4431.2004.t01-12-04035.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
5
|
Abstract
Prostaglandin E-2 (PGE-2) is an oxytocic agent in suppository form with vasodilatory effects similar to prostaglandin E-1 (PGE-1). Because some men find intracavernosal injections disagreeable, we investigated whether intraurethral PGE-2 may provide an alternative method for treating erectile dysfunction. A PGE-2 cream was made using PGE-2 suppositories (20 mg or 40 mg), 10 cc of 2% lidocaine (Xylocaine) jelly, and 40 cc of surgical lubrication. Two cc of the cream was instilled into the urethral meatus using a syringe, the cream was massaged down the urethra, and the urethra was occluded for five minutes. Treatment response was rated as no penile tumescence, partial tumescence, and full tumescence. Overall, 70 percent showed a response and 30 percent had full penile tumescence. Two of 4 men who had no tumescence using PGE-2 had a subsequent full tumescence using intracavernosal PGE-1 (15 mg), while 3 of 4 men with a partial tumescence with PGE-2 had a subsequent full tumescence using intracavernosal PGE-1 (15 mg). These data demonstrate that full penile tumescence may be achieved in impotent men using intraurethral PGE-2 cream. This pilot study supports the necessity for further investigations in a randomized double-blind manner in the use of intraurethral PGE-2 cream as a less invasive treatment alternative for erectile dysfunction.
Collapse
Affiliation(s)
- B Wolfson
- Department of Surgery, Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance
| | | | | | | | | |
Collapse
|
6
|
Singer R, Scott NE. Progression of neuropsychological deficits following toluene diisocyanate exposure. Arch Clin Neuropsychol 1987; 2:135-44. [PMID: 14591141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023] Open
Abstract
Three wharf workers were acutely exposed to toluene diisocyanate (TDI) during an accidental chemical spill. Toluene is neurotoxic as a solvent, while cyanates can cause nervous tissue injury or death by hypoxia. Chronic symptoms which occurred following the incident included headache, fatigue, concentration problems, irritability, depression, sleep disturbance, memory and sexual dysfunction. Compared with two months post-exposure, at 16 months post-exposure Full Scale IQ dropped an average of 23 points. Results from additional neuropsychological testing at 16 months post-exposure indicated severe deficits in all three subjects in memory, manual dexterity, visuomotor tracking, mental flexibility, ability to detect figure-ground relationships, and word fluency. Nerve conduction velocity testing indicated abnormal peripheral nervous system function in two of the three workers; however, its etiology is not certain. These results may be relevant to the neurotoxicity of methyl isocyanate exposure, such as occurred in Bhopal, India, where an increasing magnitude of depression, anxiety, fatigue, restlessness, and headaches 18 months post-exposure have been reported. In general, continuing decrement in mental function without concomitant environmental exposure should be considered in neuropsychological assessment of chemical toxicity.
Collapse
Affiliation(s)
- R Singer
- Mt. Sinai School of Medicine, USA
| | | |
Collapse
|